AAV-PHP.eB achieves superior neuronal transduction over AAV9 in pigtail macaques following intracerebroventricular administration
Molecular Therapy Methods & Clinical Development · 2025-12 · 33 (4) · 101636
DOI: 10.1016/j.omtm.2025.101636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Methods & Clinical Development, 2025-12. Verfasst von Michal G Fortuna und 9 weiteren Autor:innen. Beteiligte Einrichtung: Allen Institute for Brain Science, Seattle, WA, USA. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University of Washington, Allen Institute, Office of Research Infrastructure Programs.
Abstract (Originalsprache)
Adeno-associated virus (AAV) vectors are pivotal in gene therapy for neurological disorders due to their ability to enable long-term gene expression in the central nervous system (CNS). However, transducing larger brains, such as those of non-human primates (NHPs), remains challenging, necessitating alternative delivery routes and optimized capsids. This study directly compares the transduction efficiency and biodistribution of the benchmark AAV9 and its engineered derivative, AAV-PHP.eB, following intracerebroventricular (i.c.v.) administration in juvenile Macaca nemestrina. Employing a neuron-specific promoter and nuclear-localized reporter, we systematically quantified transduction across cortical, subcortical, and spinal regions. AAV-PHP.eB demonstrated significantly higher transduction rates in cortical and spinal regions compared to AAV9, despite similar expression patterns. Both vectors exhibited limited subcortical penetration and significant peripheral leakage, highlighting key challenges in CNS targeting. This is the first study to quantitatively compare AAV-PHP.eB and AAV9 in NHPs, providing valuable insights into the advantages and limitations of engineered AAV capsids for CNS gene therapy. These findings lay a critical foundation for optimizing vector designs and delivery strategies to improve outcomes in clinical applications for neurodegenerative and neurodevelopmental disorders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Allen Institute for Brain Science, Seattle, WA, USA.
- Washington National Primate Research Center, Seattle, WA, USA.
- Department of Neurological Surgery, University of Washington, Seattle, WA, USA.
- Department of Neurobiology & Biophysics, University of Washington, Seattle, WA, USA.
Förderung
- University of Washington
- Allen Institute
- Office of Research Infrastructure Programs
Zitieren
APA
Fortuna, M. G., Nyberg, L. H., Taskin, N., Hunker, A., Weed, N., Gudsnuk, K., Berg, M., Levi, B. P., Lein, E., & Ting, J. T. (2025). AAV-PHP.eB achieves superior neuronal transduction over AAV9 in pigtail macaques following intracerebroventricular administration. Molecular Therapy Methods & Clinical Development, 33(4), 101636. https://doi.org/10.1016/j.omtm.2025.101636
Vancouver
Fortuna MG, Nyberg LH, Taskin N, Hunker A, Weed N, Gudsnuk K, et al. AAV-PHP.eB achieves superior neuronal transduction over AAV9 in pigtail macaques following intracerebroventricular administration. Molecular Therapy Methods & Clinical Development. 2025;33(4):101636. doi:10.1016/j.omtm.2025.101636
BibTeX
@article{Fortuna2025,
author = {Fortuna, Michal G and Nyberg, Lyle H and Taskin, Naz and Hunker, Avery and Weed, Natalie and Gudsnuk, Kathryn and Berg, Melissa and Levi, Boaz P and Lein, Ed and Ting, Jonathan T},
title = {AAV-PHP.eB achieves superior neuronal transduction over AAV9 in pigtail macaques following intracerebroventricular administration},
journal = {Molecular Therapy Methods & Clinical Development},
year = {2025},
volume = {33},
number = {4},
pages = {101636},
doi = {10.1016/j.omtm.2025.101636}
}
EUVIMED